We are live on
!
Find out more
OM
Opaleye Management Portfolio holdings
AUM
$1.1B
Turnover
32.84%
1-Year Est. Return
197.64%
This Fund
S&P 500
This Quarter
Est. Return
+29.44%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$215M
AUM Growth
+$17.5M
(+8.8%)
Cap. Flow
-$18.3M
Cap. Flow
% of AUM
-8.51%
Top 10 Holdings %
Top 10 Hldgs %
52.76%
Holding
47
New
10
Increased
10
Reduced
9
Closed
10
Avg Time Held
0.5
years
Top 10 Avg Time Held
0.6
years
Top 20 Avg Time Held
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMAG
AMAG Pharmaceuticals
AMAG
|
+$9.06M |
| 2 |
MiMedx Group
MDXG
|
+$5.52M |
| 3 |
ADMS
Adamas Pharmaceuticals
ADMS
|
+$4.37M |
| 4 |
Neurocrine Biosciences
NBIX
|
+$3.58M |
| 5 |
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
|
+$3.43M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$10.4M |
| 2 |
Chimerix, Inc.
CMRX
|
+$9.53M |
| 3 |
Travere Therapeutics
TVTX
|
+$6.4M |
| 4 |
ARAV
Aravive, Inc. Common Stock
ARAV
|
+$5.28M |
| 5 |
GNMK
GenMark Diagnostics, Inc
GNMK
|
+$4.56M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.86% |
| 2 | Miscellaneous | 2.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Tvardi Therapeutics
TVRD
$14.3M
| $3.17M | 1.47% |
8,750
+6,528
| +294% | +$2.47M |
2014 Q4
1 quarter
|
|
|
ZSPH
27
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
| $3.16M | 1.47% |
+75,000
| New | +$3.43M |
2015 Q1
0 quarters
|
|
28
Iovance Biotherapeutics
IOVA
$6.67B
| $2.42M | 1.12% |
+200,000
| New | +$2.25M |
2015 Q1
0 quarters
|
|
29
DELISTED
Accelerate Diagnostics
AXDX
| $2.26M | 1.05% |
10,060
+60
| +0.6% | +$12.5K |
2014 Q3
2 quarters
|
|
30
Tenax Therapeutics
TENX
$56.5M
| $1.98M | 0.92% |
19
+5
| +36% | +$525K |
2014 Q4
1 quarter
|
|
31
DELISTED
Evoke Pharma
EVOK
| $1.73M | 0.8% |
1,701
+34
| +2% | +$30.7K |
2014 Q1
4 quarters
|
|
32
MacroGenics
MGNX
$215M
| $1.57M | 0.73% |
+50,000
| New | +$1.69M |
2015 Q1
0 quarters
|
|
|
BDSI
33
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $1.48M | 0.68% |
+140,500
| New | +$1.92M |
2015 Q1
0 quarters
|
|
|
CELGZ
34
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
| $1.46M | 0.68% |
490,000
-85,000
| -15% | -$269K |
2013 Q4
5 quarters
|
|
35
BioLineRX
BLRX
$10.2M
| $528K | 0.25% |
417
| – | – |
2013 Q4
5 quarters
|
|
36
InspireMD
NSPR
$22.5M
| – | – |
0
| – | – |
2013 Q4
5 quarters
|
|
|
TCON
37
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $171K | 0.08% |
+61
| New | +$160K |
2015 Q1
0 quarters
|
|
38
Alnylam Pharmaceuticals
ALNY
$31.3B
| – | – |
-29,100
| Closed | -$2.82M | – |
|
39
DELISTED
Catalyst Pharmaceutical
CPRX
| – | – |
-975,000
| Closed | -$2.9M | – |
|
40
Standard BioTools
LAB
$258M
| – | – |
-95,000
| Closed | -$3.2M | – |
|
|
ARAV
41
DELISTED
Aravive, Inc. Common Stock
ARAV
| – | – |
-39,167
| Closed | -$5.28M | – |
|
|
PRTK
42
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| – | – |
-80,000
| Closed | -$3.08M | – |
|
|
CSII
43
DELISTED
Cardiovascular Systems, Inc.
CSII
| – | – |
-125,000
| Closed | -$3.76M | – |
|
|
GNMK
44
DELISTED
GenMark Diagnostics, Inc
GNMK
| – | – |
-335,000
| Closed | -$4.56M | – |
|
|
HZNP
45
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| – | – |
-220,000
| Closed | -$2.84M | – |
|
|
PCYC
46
DELISTED
PHARMACYCLICS INC
PCYC
| – | – |
-85,000
| Closed | -$10.4M | – |
|
Similar funds
CFO
PFM
HBCM
AI
TPA
ZDA
NW
TFA
Opaleye Management's Q1 2015 Portfolio in Review
As of Q1 2015, Opaleye Management held 47 positions worth $215M, up 8.8% from $198M the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Opaleye Management withdrew a net $18.3M in Q1 2015, closing 10 positions and reducing 9 holdings. Its most notable exit was PHARMACYCLICS INC, an estimated $10.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 92% a quarter earlier, followed by Miscellaneous.
Against the trend, Opaleye Management opened a new position in AMAG Pharmaceuticals worth $10.4M.
- Opaleye Management's largest Q1 2015 buy was AMAG Pharmaceuticals: 190,000 shares worth $10.4M.
- Opaleye Management added most to Neurocrine Biosciences in Q1 2015, an estimated $3.58M increase.
- Opaleye Management's biggest Q1 2015 reduction was Chimerix, Inc., cutting an estimated $9.53M.
- Opaleye Management fully exited PHARMACYCLICS INC in Q1 2015, selling an estimated $10.4M.
- Opaleye Management's ten largest holdings make up 53% of its $215M portfolio in Q1 2015.
- Opaleye Management opened 10 new positions and closed 10 in Q1 2015.
- Opaleye Management's portfolio value rose 8.8% quarter-over-quarter to $215M.
Based on Opaleye Management's 13F filing for Q1 2015, filed 15 May 2015.